These cancers instead rely on the PARP repair pathway, making this back-up pathway a solid target for anti-cancer treatments. The key to building on this success for a wider range of cancers is ...

Therapeutics announced the presentation of new clinical data from its ongoing Phase 2 trial with stenoparib monotherapy in ...

Under the terms of the settlement, Allarity has consented, without admitting or denying the SEC’s findings, to the entry of an administrative cease-and-desist order. The settlement resolves the SEC’s ...

Scientific breakthroughs are transforming cancer treatments such as immuno-oncology, cell therapy and the synthetic lethal concept using poly (ADP-ribose) polymerase (PARP) inhibitors for breast ...

(“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated dual PARP/Wnt pathway inhibitor—as a ...

Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company ...

Allarity Therapeutics has announced a Phase 2 clinical trial to evaluate the combination of stenoparib, a dual PARP/Wnt pathway inhibitor, with temozolomide for patients with recurrent Small Cell ...

(“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated dual PARP/Wnt pathway inhibitor—as a ...

(“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated dual PARP/Wnt pathway inhibitor—as a ...

Different genomic alterations in DNA damage repair (DDR) pathways occur in 20% to 25% of ... repair defects with response to treatment with PARP inhibitors marked the first successful application ...